Institute of Life Sciences, Nalco Square, Bhubaneswar 751 023, Odisha, India; Regional Centre for Biotechnology, Faridabad-Gurgaon Expressway, Faridabad 121 001, Haryana.
Institute of Life Sciences, Nalco Square, Bhubaneswar 751 023, Odisha, India.
Int J Pharm. 2022 Mar 25;616:121526. doi: 10.1016/j.ijpharm.2022.121526. Epub 2022 Jan 30.
TNBC exhibits higher rate of chemoresistance, metastasis, and relapse among all subtypes of breast cancer. This malignant statein TNBC is due to self-renewing sub-population of cells called cancer stem cells (CSCs). They are major caveats in TNBC treatment and need to be obliterated. In this regard, we explored piperlongumine (PL) that has remarkable anti-cancerous property but poor pharmacokinetics limits its application. So, to enhance its biological activity we developed PLGA based nanoformulation for PL (PL-NPs) and examined anti-CSCs effects of PL and PL-NPs in mammospheres. Results indicated that PL-NPs have higher cellular uptake than PL in mammospheres. Further, we demonstrated that PL-NPs remarkably inhibit various characteristics of CSCs like expression of ALDH, self-renewability, chemoresistance, and EMT in mammopsheres. We next investigated the possible mechanism underlying these multi-modal effects, and found that inhibition of STAT3 might be the driving force. In order to confirm this, we used colivelin a potent synthetic peptide activator of STAT3 in combination with treatments and found that anti-CSCs effects of PL and PL-NPs were reversed. Taken together, our data indicates that PL-NPs show enhanced inhibition of CSCs through downregulation of STAT3 and provides insight into development of PL based nanomedicine for targeting CSCs in TNBC.
三阴性乳腺癌(TNBC)在所有乳腺癌亚型中表现出更高的化疗耐药性、转移率和复发率。这种 TNBC 的恶性状态是由于称为癌症干细胞(CSCs)的自我更新细胞亚群引起的。它们是 TNBC 治疗中的主要难题,需要被消除。在这方面,我们研究了具有显著抗癌特性但药代动力学不佳限制其应用的胡椒碱(PL)。因此,为了增强其生物活性,我们开发了基于 PLGA 的 PL 纳米制剂(PL-NPs),并在类乳腺球体中检查了 PL 和 PL-NPs 对 CSCs 的抑制作用。结果表明,PL-NPs 在类乳腺球体中的细胞摄取率高于 PL。此外,我们证明 PL-NPs 可显著抑制 CSCs 的多种特性,如 ALDH 的表达、自我更新能力、化疗耐药性和 EMT。接下来,我们研究了这些多模式作用的潜在机制,发现抑制 STAT3 可能是驱动力。为了证实这一点,我们使用了 colivelin,一种有效的 STAT3 合成肽激活剂,与治疗联合使用,发现 PL 和 PL-NPs 的抗 CSCs 作用被逆转。总之,我们的数据表明,PL-NPs 通过下调 STAT3 显示出增强的 CSCs 抑制作用,并为开发基于 PL 的纳米医学以靶向 TNBC 中的 CSCs 提供了深入了解。